The 'prion-like' nature of neurodegenerative diseases has been mooted for a number of years. The central concept is of self-propagating misfolded proteins spreading from neuron to neuron, associated with more or less stereotypical patterns of neurodegeneration in specific diseases. Apart from prion protein (PrP) in the archetypal prion diseases, the evidence that amyloid-b, tau, and now-in this issue of Brain--synuclein, all propagate through the brain is compelling, with implications for the pathogenesis of Alzheimer's disease, frontotemporal dementias and other tauopathies, and Parkinson's disease. The spread of neurodegenerative diseases through protein misfolding thus appears to be a truly generic phenomenon. Why does this matter and where does it take us? The inescapable fact of neurodegenerative diseases is that we currently have no effective way of treating them. However, the more we learn about pathogenesis, the more likely we are to identify therapeutic approaches that could succeed. So how does the spreading protein hypothesis help us? Will inhibiting cell-to-cell transmission of these pathological conformers prevent neurodegeneration? Importantly, what is the connection between spread of proteins and actual neurodegeneration? The study by Masuda-Suzukake et al. (2013) goes beyond confirming the place of -synuclein on the list of self-propagating proteins. It raises interesting questions about the link-or lack of it-between transmission of pathological proteins and their neurotoxic effects. The relationship between toxicity and 'infectivity' is an important phenomenon in prion and other protein misfolding disorders. Increasing our insights into this is likely to inform our approach to understanding and treating these diseases.
The work published here by Masuda-Suzukake et al. (2013) is the latest in a series of experiments addressing the spread of proteins associated with neurodegenerative disorders based on in vitro data, clinical observations (the presence of Lewy bodies in foetal dopaminergic cells years after grafting into the brains of patients with Parkinson's disease) and in vivo models. That tau, amyloid-b and -synuclein are all capable of the type of templated conformational change that was first described for prions, and that these changes could spread between cells, was first established in cell models (Petkova et al., 2005; Desplats et al., 2009; Frost et al., 2009) . Like prions, these proteins also form distinct conformers in vivo, and a number of elegant experiments followed confirming that mutant tau, amyloid-b and mutant -synuclein cause spread in regional pathology and disease progression in mouse models (Clavaguera et al., 2009; Jucker and Walker, 2011; Luk et al., 2012a; Mougenot et al., 2012) . Masuda-Suzukake and colleagues have now shown the propagation of native, wild-type -synuclein fibrils throughout the brains of mice, proving the intrinsic capacity of the normal protein for pathological structural conversion and spread; they have successfully modelled sporadic disease in vivo. The authors injected the striatum of wild-type mice with different fibrillar -synuclein preparations: insoluble monomers of mouse and human protein, and-importantly-extracts of sarkosyl-insoluble -synuclein from the brain of a patient with dementia with Lewy bodies. All treatments caused -synuclein accumulation and spread and Lewy body-like pathology in different brain regions. What is remarkable here is the prion-like species-barrier crossing effect: injection of human synuclein oligomers results in the accumulation, over time, of mouse -synuclein aggregates. However, we should be cautious about taking the prion analogy further. Until transmission of these disorders by repeated passage is shown, we are looking at propagation within individual brains rather than the true transmissibility between animals that characterizes prion diseases.
The work closely follows a paper by Luk et al. (2012b) where synthetic oligomeric mouse -synuclein injected into the substantia nigra of wild-type mice similarly induced spread of -synuclein throughout the brain, but here it recapitulated the Parkinsonian phenotype, with loss of dopaminergic nigral neurons, reduced striatal dopamine levels and motor deficits. While both studies show the cell-to-cell spread of wild-type -synuclein pathology, only in one is there a convincing neurodegenerative phenotype. Masuda-Suzukake et al. (2013) show changes in levels of enkephalin in the amygdala and globus pallidus in injected mice, and interpret this as reflecting neuronal dysfunction (albeit without clinical signs) resulting from aggregate pathology, but the mechanistic link between propagation of pathological protein and neurodegeneration is more convincing in the study by Luk et al. (2012b) .
The separation between misfolded protein spread and neurodegeneration in Masuda-Suzukake et al's study does not undermine the value of the model, however. Instead, it speaks to the important concept that protein misfolding disorders have two aspects: first, within cell (i.e. cell autonomous) processes, that cause cellular dysfunction and ultimately neurodegeneration; and second, between cell (i.e. non-cell autonomous) processes, through which pathology spreads. The landmark study by Clavaguera et al. (2009) describing prion-like transmission of mutant human P301S tau in mice similarly showed spread of pathology without neurodegeneration, and in prion diseases, the fact that dissociation of toxic species (that kill neurons) and infectious agent (propagating prion protein) can occur, is well established (Hill and Collinge, 2003; Mallucci et al., 2003; Sandberg et al., 2011) . So cell-autonomous and non-cell autonomous mechanisms co-exist, but do not necessarily impinge equally on neuronal death in all models. It is likely that both derive from the same core problem, the accumulation of misfolded proteins. There is strong evidence in prion disease that the misfolded protein load causes sustained activation of cellular pathways such as the unfolded protein response within neurons, leading to-cell autonomous-neuronal death (Moreno et al., 2012) . The same mechanism may occur in Alzheimer's and Parkinson's diseases, since unfolded protein response overactivation also occurs in these disorders. The link between the toxicity of the protein load within cells and the spread of proteins between them is not clear, however, since high levels of misfolded protein in the brain do not necessarily correlate with toxicity in individual neurons, as we see here.
So will inhibiting cell-to-cell transmission of these pathological conformers prevent neurodegeneration? Intuitively, containing spread must be beneficial, preventing the progressive deterioration that characterizes the clinical evolution of these diseases as further brain regions are 'recruited' over time. The question is how to do this? One approach is to administer disease-specific antimisfolded-protein antibodies, as has been proposed for tau and SOD1. Alternatively, are there generic mechanisms of spread that could be targeted? The problem is that we do not yet know what these are. It is clear that there are common structural features of oligomeric forms of these proteins: antibodies raised against oligomers of prion protein also detect oligomeric forms of a number of other amyloid proteins, including amyloid-b (Kayed et al., 2003) . If such structural features were involved in a universal protein propagation mechanism, they could represent a common therapeutic target for many neurodegenerative diseases. Further, there may be generic cellular pathways, including exosomal and synaptic release mechanisms underlying pathological spreading that could also potentially be targeted. Indeed, the neuroanatomical basis for this propagation was recently established by the demonstration of trans-synaptic spread of mutant tau (de Calignon et al., 2012; Liu et al., 2012) , although exactly how this occurs is still unclear.
The discovery of generic phenomena such as the spread of misfolded proteins, offers stimulating insights into neurodegenerative diseases that may well lead to new therapeutic approaches. However, we still need to understand much more about these processes at a molecular level, and how cell-autonomous and non-cell autonomous mechanisms relate to each other, before we can know which of these processes to target for therapy in these disorders.
